摘要
目的:观察表阿霉素为主的新辅助化疗治疗局部晚期乳腺癌的临床疗效。方法:48例局部晚期乳腺癌患者接受第1天表阿霉素50 mg/m2,静脉推注,CTX 600 mg/m25,-Fu 500 mg/m2,静脉滴注第1、8天。每3周为1个疗程,共3个疗程。分别观察新辅助化疗后区域淋巴结和肿瘤原发病灶的缓解情况,并观察毒性反应。结果:原发病灶临床有效率为87.5%(42/48),其中完全缓解(CR)27.1%(13/48),部分缓解(PR)60.4%(29/48),疾病稳定(SD)12.5%(6/48)。病理完全缓解率为16.7%(8/48)。毒性反应主要为恶心、呕吐、白细胞减少症、脱发等,无败血症和死亡病例。结论:以表阿霉素为主的新辅助化疗治疗局部晚期乳腺癌疗效较高,心脏毒性不良反应小,耐受性较好。
Objective To observe the clinical effect of neoadjuvant chemotherapy with Pharmorubicin for local advanced breast cancer.Method Forty-eight patients with local advanced breast cancer received intravenous injection of Pharmorubicin（50 mg/m2）,on the first day,intravenous drip of CTX（600 mg/m2）,and 5-Fu（500 mg/m2）,on the first day and eighth day.Every three weeks was a course,and a total of three courses.The relief of regional lymph nodes and primary tumor lesion after neoadjuvant chemotherapy were observed respectively,also the toxic reaction.Results The clinical effective rate in primary lesion was 87.5%（42/48）,including complete remission（CR） 27.1%（13/48）,part remission（PR） 60.4%（29/48） and stable disease（SD） 12.5%（6/48）.Pathologic complete remission rate was 16.7%（8/48）.The toxic reactions mainly were nausea,vomiting,leukopenia,hair loss and so on,no sepsis and deaths.Conclusion Neoadjuvant chemotherapy with Pharmorubicin treating local advanced breast cancer has high effects,less heart toxicity and good tolerance.
出处
《吉林医学》
CAS
2011年第7期1303-1304,共2页
Jilin Medical Journal
关键词
表阿霉素
乳腺癌
新辅助化疗
Pharmorubicin
Breast cancer
Neoadjuvant chemotherapy
